BioSpace News Archive

Philadelphia-based software company eResearchTechnology (ERT), which offers software used in hundreds of clinical trials, has suffered a ransomware attack.

Together, the university and AVROBIO will look into an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.

The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021.

Only a year after buying cancer specialist Celgene for $74 billion, Bristol Myers Squibb announced it is buying cardiology company MyoKardia for about $13.1 billion. The deal is expected to close before the end of the year.

New long-term safety and efficacy data highlights the medication’s capabilities in allowing patients to maintain fewer migraine days over a period of five years.

Grace Wei, Ph.D., who founded Encellin in 2016 with co-founder Crystal Nyitray, Ph.D., shared some of her lessons during a recent Innovation Centre Denmark, Silicon Valley presentation for would-be biotech entrepreneurs.

The prize was awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for their efforts to identify the virus. Prior to their work, the medical world was only aware of Hepatitis A and B.

There are over 170 COVID-19 vaccine candidates at various stages of development, and all but a few of them take the traditional intramuscular approach. But could intranasal delivery ease the logistical nightmare we face in exterminating the pandemic across the globe?

Scientific luminary and MacArthur Fellowship winner Kevin Eggan, Ph.D. will lead early-stage research at rare disease-focused BioMarin.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the execution of a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop ZEN-3694 for multiple oncology indications. For the first clinical study under the CRADA, NCI is co-collaborating with Zenith and Bristol Myers Squibb (BMS) to investigate the combination of Zenith’s epigenetic therapy – BET inhibitor ZEN-3694 – with i